

**REPORT OF THE TRUSTEES AND
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021
FOR
BRITISH NUCLEAR MEDICINE SOCIETY**

E R Grove & Co Limited
Grove House
Coombs Wood Court
Steel Park Road
Halesowen
West Midlands
B62 8BF

BRITISH NUCLEAR MEDICINE SOCIETY

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021**

	Page
Report of the Trustees	1 to 3
Independent Examiner's Report	4
Statement of Financial Activities	5
Balance Sheet	6
Notes to the Financial Statements	7 to 12

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2021**

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2021. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

British Nuclear Medicine Society is dedicated to promoting the multidisciplinary practice of high quality nuclear medicine for the benefit of patients.

The specific objectives of the British Nuclear Medicine Society are to:

- 1 Raise the profile of nuclear medicine
- 2 Engage with all health care providers involved in the clinical use of radionuclides
- 3 Provide a forum for the communication of advances in nuclear medicine
- 4 Provide resources and encourage the provision of education and training to support continuing professional development.
- 5 Represent nuclear medicine with official bodies and on advisory committees
- 6 Develop and promote standards and guidelines for the safe and effective practice of nuclear medicine
- 7 Promote nuclear medicine research and development
- 8 Improve the level of support to isolated departments
- 9 Provide greater information for the benefit of patients
- 10 Promote and support the recertification/revalidation of practitioners
- 11 Maintain an appropriate charitable status.

Significant activities

In order for the charity to achieve its aim BNMS engage in the following activities:

- Raising the profile of nuclear medicine through the website, scientific meetings and attendance of careers fairs.
- Engaging with other professional organisations, including British Institute of Radiology, British Cardiology Society, Institute of Physics and Engineering in Medicine, Royal College of Physicians, Royal College of Radiologists, Royal College of Surgeons, Royal College of Nursing, Society and College of Radiographers and Society of Radiological Protection.
- Providing a forum for the communication of advances in nuclear medicine through annual and regional scientific meetings, Nuclear Medicine Communications (the official BNMS journal) and the BNMS website.
- Leading in the provision of education and training to support the development of nuclear medicine
- Representing the specialty on relevant official bodies and advisory committees
- Developing and promoting standards and guidelines for the safe practice of nuclear medicine.
- Promoting nuclear medicine research and development by engaging with academic institutions and industry to promote research leading to new developments and improvements in clinical practice.

Public benefit

The public benefits from the activities of the British Nuclear Medicine Society through the pursuit of its specific objectives including the development and promotion of standards and guidelines for the safe and effective practice of nuclear medicine, the promotion of nuclear medicine research and development and the provision of greater information for the public on the BNMS website.

REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2021

ACHIEVEMENT AND PERFORMANCE

Charitable activities

The British Nuclear Medicine Society held two scientific and educational meetings this year around the UK, the results of which are as follows:

	Spring Virtual £	Autumn Virtual £	Total £
Income			
Commercial exhibition income	18,200	17,217	35,417
Annual conference delegate registration fees	15,805	20,784	36,589
	34,005	38,001	72,005
Less: Scientific meeting expenses	11,965	17,256	29,221
Surplus	22,040	20,745	42,784

Fundraising activities

The British Nuclear Medicine Society generates income from membership fees, from royalties received through "Nuclear Medicine Communications" (the scientific journal of the BNMS) as well registration and exhibitor fees from those attendees at the annual and educational meetings of the Society.

Covid-19 Pandemic

The onset of the Pandemic caused significant disruption to the society's operations and scientific meetings.

The charity has introduced a few changes to our working practices to safeguard our employees and trustees. These include, closing the head office and moving to home working.

We are pleased that membership numbers have been steady during the year and that most of the costs scientific meeting s that were cancelled, were recovered by the charity for future meetings.

The ongoing pandemic brings continued uncertainty to the wider economy and our own operations. However, the trustees are confident the charity is well placed to deal with these challenges.

FUTURE PLANS

The society will continue to promote the multidisciplinary practice of nuclear medicine for the benefit of patients. It plans to continue holding regular meetings throughout the country and will further encourage regional networks.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

08082786 (England and Wales)

Registered Charity number

1150234

Registered office

Royal College of Physicians
11 St Andrews Place
Regents Park
London
London
NW1 4LE

Trustees

Who are also directors

Mrs J Croasdale	Radiopharmacist
Dr R Graham	Radiologist
Dr S Redman	Clinical Scientist
Dr J R Buscombe	Nuclear Medicine Physician

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2021**

REFERENCE AND ADMINISTRATIVE DETAILS

Independent Examiner

E R Grove & Co Limited
Grove House
Coombs Wood Court
Steel Park Road
Halesowen
West Midlands
B62 8BF

Approved by order of the board of trustees on 17 May 2022 and signed on its behalf by:

Dr J R Buscombe - Trustee

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF BRITISH NUCLEAR MEDICINE SOCIETY

Independent examiner's report to the trustees of British Nuclear Medicine Society ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2021.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Steven Lomas
Senior Statutory Auditor
E R Grove & Co Limited
Grove House
Coombs Wood Court
Steel Park Road
Halesowen
West Midlands
B62 8BF

17 May 2022

BRITISH NUCLEAR MEDICINE SOCIETY
STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2021

	Notes	Unrestricted fund £	Restricted fund £	2021 Total funds £	2020 Total funds £
INCOME AND ENDOWMENTS FROM					
Other trading activities	2	138,517	5	138,522	82,144
Investment income	3	834	1	835	1,304
Other income		61,192	-	61,192	69,981
Total		<u>200,543</u>	<u>6</u>	<u>200,549</u>	<u>153,429</u>
EXPENDITURE ON					
Raising funds	4	171,070	-	171,070	170,544
NET INCOME/(EXPENDITURE)		<u>29,473</u>	<u>6</u>	<u>29,479</u>	<u>(17,115)</u>
RECONCILIATION OF FUNDS					
Total funds brought forward		311,247	14,362	325,609	342,724
TOTAL FUNDS CARRIED FORWARD		<u>340,720</u>	<u>14,368</u>	<u>355,088</u>	<u>325,609</u>

The notes form part of these financial statements

BRITISH NUCLEAR MEDICINE SOCIETY (REGISTERED NUMBER: 08082786)

**BALANCE SHEET
31 DECEMBER 2021**

	Notes	Unrestricted fund £	Restricted fund £	2021 Total funds £	2020 Total funds £
FIXED ASSETS					
Tangible assets	9	4,623	-	4,623	6,724
CURRENT ASSETS					
Debtors	10	203,911	-	203,911	151,916
Cash at bank		<u>239,650</u>	<u>14,368</u>	<u>254,018</u>	<u>232,712</u>
		443,561	14,368	457,929	384,628
CREDITORS					
Amounts falling due within one year	11	(107,464)	-	(107,464)	(65,743)
NET CURRENT ASSETS		<u>336,097</u>	<u>14,368</u>	<u>350,465</u>	<u>318,885</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		340,720	14,368	355,088	325,609
NET ASSETS		<u>340,720</u>	<u>14,368</u>	<u>355,088</u>	<u>325,609</u>
FUNDS	12				
Unrestricted funds				340,720	311,247
Restricted funds				<u>14,368</u>	<u>14,362</u>
TOTAL FUNDS				<u>355,088</u>	<u>325,609</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2021.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2021 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 17 May 2022 and were signed on its behalf by:

Dr J R Buscombe - Trustee

The notes form part of these financial statements

BRITISH NUCLEAR MEDICINE SOCIETY
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Exhibition income is recognised in the Statement of Financial Activities in the year that the exhibition is held.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Exhibition expense are recognised in the Statement of Financial Activities in the year that the exhibition is held.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings	- 15% on reducing balance
Computer equipment	- 33% on reducing balance

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension costs and other post-retirement benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

2. OTHER TRADING ACTIVITIES

	2021	2020
	£	£
Commercial exhibition income	35,417	4,500
Annual conference delegate registration fees	36,589	5,900
Commission received	955	856
Royalties received	65,594	70,617
Other project income	(33)	271
	<u>138,522</u>	<u>82,144</u>

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2021**

3. INVESTMENT INCOME

	2021	2020
	£	£
Deposit account interest	<u>835</u>	<u>1,304</u>

4. RAISING FUNDS

Raising donations and legacies

	2021	2020
	£	£
Support costs	<u>93,783</u>	<u>114,832</u>

5. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2021	2020
	£	£
Other assurance services	4,600	5,000
Depreciation - owned assets	2,217	3,446
Deficit on disposal of fixed assets	<u>-</u>	<u>248</u>

6. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2021 nor for the year ended 31 December 2020.

Trustees' expenses

Expenses of £1,355 (2019: £6,135) were paid to the trustees during the year.

7. STAFF COSTS

The average monthly number of employees during the year was as follows:

	2021	2020
	<u>2</u>	<u>3</u>
Administrative		

No employees received emoluments in excess of £60,000.

8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted fund £	Restricted fund £	Total funds £
INCOME AND ENDOWMENTS FROM			
Other trading activities	82,144	-	82,144
Investment income	1,291	13	1,304
Other Income	<u>69,981</u>	<u>-</u>	<u>69,981</u>
Total	<u>153,416</u>	<u>13</u>	<u>153,429</u>
EXPENDITURE ON			
Raising funds	170,544	-	170,544
NET INCOME/(EXPENDITURE)	<u>(17,128)</u>	<u>13</u>	<u>(17,115)</u>

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2021**

8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued			
	Unrestricted fund £	Restricted fund £	Total funds £
RECONCILIATION OF FUNDS			
Total funds brought forward	328,375	14,349	342,724
TOTAL FUNDS CARRIED FORWARD	<u>311,247</u>	<u>14,362</u>	<u>325,609</u>
9. TANGIBLE FIXED ASSETS			
	Fixtures and fittings £	Computer equipment £	Totals £
COST			
At 1 January 2021	789	30,102	30,891
Additions	116	-	116
At 31 December 2021	<u>905</u>	<u>30,102</u>	<u>31,007</u>
DEPRECIATION			
At 1 January 2021	611	23,556	24,167
Charge for year	35	2,182	2,217
At 31 December 2021	<u>646</u>	<u>25,738</u>	<u>26,384</u>
NET BOOK VALUE			
At 31 December 2021	<u>259</u>	<u>4,364</u>	<u>4,623</u>
At 31 December 2020	<u>178</u>	<u>6,546</u>	<u>6,724</u>
10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR			
	2021	2020	
	£	£	
Trade debtors	31,897	2,773	
Other debtors	101,618	60,015	
VAT	-	15,067	
Prepayments and accrued income	70,396	74,061	
	<u>203,911</u>	<u>151,916</u>	

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2021**

11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2021 £	2020 £
Trade creditors	35,147	51,736
Social security and other taxes	2,435	66
VAT	2,388	-
Other creditors	63,591	10,941
Accrued expenses	3,903	3,000
	<u>107,464</u>	<u>65,743</u>

12. MOVEMENT IN FUNDS

	At 1.1.21 £	Net movement in funds £	At 31.12.21 £
Unrestricted funds			
General fund	311,247	29,473	340,720
Restricted funds			
Ross Breen Fund	14,362	6	14,368
TOTAL FUNDS	<u>325,609</u>	<u>29,479</u>	<u>355,088</u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	200,543	(171,070)	29,473
Restricted funds			
Ross Breen Fund	6	-	6
TOTAL FUNDS	<u>200,549</u>	<u>(171,070)</u>	<u>29,479</u>

Comparatives for movement in funds

	At 1.1.20 £	Net movement in funds £	At 31.12.20 £
Unrestricted funds			
General fund	328,375	(17,128)	311,247
Restricted funds			
Ross Breen Fund	14,349	13	14,362
TOTAL FUNDS	<u>342,724</u>	<u>(17,115)</u>	<u>325,609</u>

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2021**

12. MOVEMENT IN FUNDS - continued

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	153,416	(170,544)	(17,128)
Restricted funds			
Ross Breen Fund	13	-	13
TOTAL FUNDS	<u>153,429</u>	<u>(170,544)</u>	<u>(17,115)</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.20 £	Net movement in funds £	At 31.12.21 £
Unrestricted funds			
General fund	328,375	12,345	340,720
Restricted funds			
Ross Breen Fund	14,349	19	14,368
TOTAL FUNDS	<u>342,724</u>	<u>12,364</u>	<u>355,088</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	353,959	(341,614)	12,345
Restricted funds			
Ross Breen Fund	19	-	19
TOTAL FUNDS	<u>353,978</u>	<u>(341,614)</u>	<u>12,364</u>

The Ros Breen Fund was established in memory of Ros Breen, who was Superintendent Radiographer in Nuclear Medicine at Southampton General Hospital. The fund is invested in a capital reserve bank account and the interest earned is then used to provide grants to members of the Technology Group.

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2021**

13. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 December 2021.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.